Tailoring HIV Curative Strategies to the Participant (UM1 Clinical Trial Not Allowed)
ID: 353103Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353103

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Tailoring HIV Curative Strategies to the Participant," aimed at developing clinical research platforms for tailored HIV curative strategies through cooperative agreements. The initiative seeks to fund 2-3 multidisciplinary projects with a total budget of $7 million for fiscal year 2025, focusing on proof-of-concept studies that target participants' unique HIV reservoirs and immunologic profiles, while avoiding clinical trial proposals. Interested applicants must propose innovative techniques for profiling these reservoirs and emphasize tailored immunologic approaches, with applications due by July 30, 2024. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-011.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-011-Full-Announcement.html
    RFA-AI-24-011.html
    The Department of Health and Human Services has announced a funding opportunity to develop clinical research platforms for tailored HIV curative strategies, primarily through collaborative multidisciplinary teams. The National Institutes of Health (NIH)'s National Institute of Allergy and Infectious Diseases (NIAID) seeks to fund 2-3 projects with a total budget of $7 million for fiscal year 2025. This initiative aims to inform broad-based curative strategies by conducting proof-of-concept studies that target participants’ unique HIV reservoirs and immunologic profiles. Applicants must propose innovative techniques to accurately profile these reservoirs while emphasizing two tailored immunologic approaches and latency-reactivating strategies. The application process includes detailed instructions for submission via Grants.gov and requires compliance with NIH policies. The program is designed to avoid clinical trial proposals and focuses on pre-clinical and basic research. Evaluation criteria will include significance, investigator qualifications, innovation, approach robustness, and environmental factors, with a strong emphasis on research impact and feasibility within a five-year project period.
    Similar Opportunities
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The objective of this grant is to encourage the exploration of novel therapeutic approaches that can eliminate challenging HIV proteins through mechanisms such as small molecule interventions that block translation or facilitate RNA degradation. This initiative is crucial for advancing HIV-related research and therapies, emphasizing the need for innovative drug discovery paradigms focused on intracellular HIV targets. Eligible applicants can receive funding up to $275,000 over a two-year period, with key submission dates including an earliest application date of November 4, 2024, and a close date of December 4, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-064.html.
    Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)." This initiative aims to investigate the mechanisms underlying the interactions between HIV-associated neuroinflammation and the persistence of HIV in the central nervous system (CNS), despite effective antiretroviral therapy, with a focus on developing novel therapeutic strategies. The program encourages the use of advanced methodologies, including human tissue samples, organoid models, and single-cell technologies, to explore the dynamics of CNS reservoirs and associated co-morbidities. A total of $4.5 million is available to fund 8-10 awards in fiscal year 2025, with applications due by November 9, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life" (MIEL) under grant number RFA-AI-24-029. This initiative aims to support basic and applied research focused on understanding how immunity to HIV can be developed and maintained in children from birth to under 12 years old, particularly through the study of prophylactic vaccinations and broadly neutralizing antibodies (bNAbs). The NIH plans to commit $3 million for FY 2025 to fund 3-4 awards, with individual budgets not exceeding $750,000 per year. Applications are due by October 10, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.